Skip to Main Content

60

Views

2

CrossRef citations to date

0

Altmetric

Original Research

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

Vybhav JettyDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USACorrespondence[email protected]

,

Charles J GlueckDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Kevin LeeDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Naila GoldenbergDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Marloe PrinceDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Ashwin KumarDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Michael GoldenbergDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Ishan AnandDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

&

Ping WangDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (2)